542934 CBPL

Chandra Bhagat Pharma Share Price

₹69.00 -2.49 (-3.48%)

23 Nov, 2024 15:29

SIP TrendupStart SIP in CBPL

Start SIP

Performance

  • Low
  • ₹0
  • High
  • ₹0
  • 52 Week Low
  • ₹0
  • 52 Week High
  • ₹0
  • Open Price₹0
  • Previous Close₹0
  • Volume0

Investment Returns

  • Over 1 Month -2.8%
  • Over 3 Month -9.21%
  • Over 6 Month -41.97%
  • Over 1 Year -37.27%
SIP Lightning

Smart Investing Starts Here Start SIP with Chandra Bhagat Pharma for Steady Growth!

Invest Now

Chandra Bhagat Pharma Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

Chandra Bhagat Pharma Financials

Chandra Bhagat Pharma Technicals

EMA & SMA

Current Price
₹69.00
-2.49 (-3.48%)
pointer
  • stock-down_img
  • Bullish Moving Average 0
  • stock-up_img
  • Bearish Moving Average 16
  • 20 Day
  • ₹70.08
  • 50 Day
  • ₹73.58
  • 100 Day
  • ₹81.87
  • 200 Day
  • ₹92.16

Resistance and Support

69 Pivot Speed
  • R3 69.00
  • R2 69.00
  • R1 69.00
  • S1 69.00
  • S2 69.00
  • S3 69.00

What's your outlook on Chandra Bhagat Pharma?

You can only vote for once

Chandra Bhagat Pharma Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-11-13 Half Yearly Results
2024-05-30 Audited Results
2023-11-09 Half Yearly Results
2023-05-22 Audited Results
2022-11-14 Half Yearly Results

Chandra Bhagat Pharma F&O

Chandra Bhagat Pharma Shareholding Pattern

No data available.

About Chandra Bhagat Pharma

  • NSE Symbol
  • CBPL
  • BSE Symbol
  • 542934
  • ISIN
  • INE07QQ01016

Similar Stocks to Chandra Bhagat Pharma

Chandra Bhagat Pharma FAQs

Chandra Bhagat Pharma share price is ₹69 As on 23 November, 2024 | 15:15

The Market Cap of Chandra Bhagat Pharma is ₹52.1 Cr As on 23 November, 2024 | 15:15

The P/E ratio of Chandra Bhagat Pharma is As on 23 November, 2024 | 15:15

The PB ratio of Chandra Bhagat Pharma is 1.8 As on 23 November, 2024 | 15:15

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23